The objective of this study is to evaluate the long-term safety of AAV-GAD delivered bilaterally to the subthalamic nuclei (STN) in participants with Parkinson's disease.
The duration of individual participation in this study will be approximately 54 months for participants who received AAV-GAD in Study MGT-GAD-025 and approximately 60 months for participants who received sham surgery in Study MGT-GAD-025.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
13
Bilateral infusion of AAV-GAD
Yale University
New Haven, Connecticut, United States
Henry Ford West Bloomfield Hospital
West Bloomfield, Michigan, United States
Weill Cornell Medicine
New York, New York, United States
Columbia University Irving Medical Center
New York, New York, United States
Number of participants with study drug-related adverse events and serious adverse events
Time frame: From study start until Month 60 post treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
West Virginia University
Morgantown, West Virginia, United States